A5063742102- Autism Spectrum Disorder Research
- Child Nutrition and Feeding Issues
- Family and Disability Support Research
- Child Development and Digital Technology
- Down syndrome and intellectual disability research
- Epilepsy research and treatment
- Attention Deficit Hyperactivity Disorder
- Genetics and Neurodevelopmental Disorders
- Behavioral and Psychological Studies
- Obsessive-Compulsive Spectrum Disorders
- Neonatal and fetal brain pathology
- Virology and Viral Diseases
- Hearing, Cochlea, Tinnitus, Genetics
- Migraine and Headache Studies
- Pain Mechanisms and Treatments
- Botulinum Toxin and Related Neurological Disorders
- Alzheimer's disease research and treatments
- Pharmacological Effects and Toxicity Studies
- Cardiovascular Syncope and Autonomic Disorders
- Statistical Methods in Clinical Trials
- Vestibular and auditory disorders
- Connexins and lens biology
- Frailty in Older Adults
- Mobile Health and mHealth Applications
- Cancer Treatment and Pharmacology
Janssen (United States)
2013-2023
Janssen (Belgium)
2012-2021
Ithaka Harbors
2020
National Institute of Neurological Disorders and Stroke
2014
International Neuromodulation Society
2013
Johnson & Johnson (United States)
2008-2011
Memorial Hospital
2010
Icahn School of Medicine at Mount Sinai
2003
New York Proton Center
2003
Mount Sinai Medical Center
2001
In the United States, estimates indicate there are between 250,000 and 400,000 individuals with Down syndrome (DS), nearly all will develop Alzheimer's disease (AD) pathology starting in their 30s. With current lifespan being 55 to 60 years, approximately 70% dementia, if life expectancy continues increase, number of developing AD concomitantly increase. Pathogenic mechanistic links DS prompted Association partner Linda Crnic Institute for Syndrome Global Foundation at a workshop experts...
OBJECTIVE. Currently, no drugs are Food and Drug Administration-approved for migraine prophylaxis in pediatric patients. The objective of this study was to evaluate the efficacy safety topiramate prevention adolescents. METHODS. Adolescents (12–17 years age) with a ≥6-month history were assigned randomly receive 16 weeks daily treatment (50 or 100 mg/day) placebo. primary measure percent reduction monthly attacks, use 48-hour rule, from prospective baseline period last 12 double-blind phase....
Adults with Down syndrome (DS) represent an enriched population for the development of Alzheimer's disease (AD), which could aid study therapeutic interventions, and in turn, benefit from discoveries made other AD populations.1) Understand relationship between tau pathology age, amyloid deposition, neurodegeneration (MRI FDG PET), cognitive functional performance; 2) detect differentiate AD-specific changes DS-specific brain longitudinal MRI.Twelve non-demented adults, ages 30 to 60, DS were...
To gain further knowledge on the preclinical phase of Alzheimer's disease (AD), we sought to characterize cognitive performance, neuroimaging and plasma-based AD biomarkers in a cohort non-demented adults with down syndrome (DS). The goal biomarker Initiative (DSBI) pilot is test feasibility this approach for future multicenter studies. We enrolled 12 participants DS between ages 30-60 years old. Participants underwent extensive testing, volumetric MRI, amyloid positron emission tomography...
A number of recent studies using accelerometer features as input to machine learning classifiers show promising results for automatically detecting stereotypical motor movements (SMM) in individuals with Autism Spectrum Disorder (ASD). However, replicating these across different types accelerometers and their position on the body still remains a challenge. We introduce new set this domain based recurrence plot quantification analyses that are orientation invariant able capture non-linear...
Down Syndrome (DS) adults experience accumulation of Alzheimer's disease (AD)-like amyloid plaques and tangles a high incidence dementia could provide an enriched population to study AD-targeted treatments. However, evaluate effects therapeutic intervention, it is necessary dissociate the contributions DS AD from overall phenotype. Imaging biomarkers offer potential characterize stratify patients who will worsen clinically but have yielded mixed findings in subjects.We evaluated 18F...
The relationship between sleep (caregiver-reported and actigraphy-measured) other caregiver-reported behaviors in children adults with autism spectrum disorder (ASD) was examined, including the use of machine learning to identify variables important predicting anxiety ASD.Caregivers ASD (n = 144) typically developing (TD) 41) participants reported on behaviors. wore an actigraphy device at nighttime during 8 or 10-week non-interventional study. Mean variability measures for week preceding...
In the First-In-Human (FIH), 39-week, randomized, adaptive design study, safety, tolerability, pharmacokinetics and biomarkers were measured in patients with mild-to-moderate Alzheimer's disease (AD) after infusion of a humanized monoclonal antibody to amyloid β, AAB-003 (NCT01193608; registered 19 August 2010). was developed by modifying bapineuzumab reduce Fc-receptor-mediated effector function as strategy removal from vessel walls associated amyloid-related imaging abnormalities...
The Usher syndrome, the most frequent cause of deafness and concurrent blindness, occurs with increased frequency in Ashkenazi Jews. authors this study demonstrated a founder mutation for common form type 1 syndrome that probably occurred 350 years ago.
Autism Behavior Inventory (ABI) is a new measure for assessing changes in core and associated symptoms of autism spectrum disorder (ASD) participants (ages: 3 years-adulthood) diagnosed with ASD. It web-based tool five domains (two ASD domains: social communication, restrictive repetitive behaviors; three mental health, self-regulation, challenging behavior). This study describes design, development, initial psychometric properties the ABI.ABI items were generated following review existing...
To assess efficacy and safety of fulranumab, a fully human monoclonal antibody against nerve growth factor, in patients with diabetic peripheral neuropathic pain (DPNP).In this phase II, double-blind, placebo-controlled trial, moderate to severe DPNP were randomized treatments fulranumab (1, 3, or 10 mg) placebo administered subcutaneously every 4 weeks.Because early study termination (clinical hold) by the US Food Drug Administration, 77 (intent-to-treat) planned 200 enrolled. The primary...
Objective: To test usability and optimize the Janssen Autism Knowledge Engine (JAKE®) system's components, biosensors, procedures used for objective measurement of core associated symptoms autism spectrum disorder (ASD) in clinical trials. Methods: A prospective, observational study 29 children adolescents with ASD using JAKE system was conducted at three sites United States. This designed to establish feasibility learn practical aspects its implementation. In addition information collected...
Abstract Background Reduction or differences in facial expression are a core diagnostic feature of autism spectrum disorder (ASD), yet evidence regarding the extent this discrepancy is limited and inconsistent. Use automated detection technology enables accurate efficient tracking expressions that has potential to identify individual response differences. Methods Children adults with ASD ( N = 124) typically developing (TD, 41) were shown short clips “funny videos.” Using analysis software,...
Keratins are intermediate filaments of epithelial cells. Mutations in keratin genes expressed skin lead to human disorders, including epidermolysis bullosa simplex and epidermolytic hyperkeratosis. We examined the role 4 (K4) maintaining integrity internal linings by using gene targeting generate mice containing a null mutation K4 gene. Homozygous that do not express develop spectrum phenotypes affect several organs which esophagus, tongue, cornea. The cellular include basal hyperplasia,...
To evaluate the efficacy and safety of adjunctive topiramate (sprinkle capsules or oral liquid) in reducing daily rates partial-onset seizures (POS) infants with refractory POS.In this double-blind, placebo-controlled, parallel-group, international study, (n = 149) clinical EEG evidence POS were randomly allocated (1:1:1:1) to receive 5, 15, 25 mg/kg/d placebo for 20 days. The primary variable was median percentage reductions rate from baseline final assessment as recorded on a 48-hour...
Summary Purpose: To assess the efficacy, safety, and tolerability of adjunctive carisbamate treatment at 800 mg/day 1,200 in patients with partial‐onset seizures (POS). Methods: Patients ≥16 years age an established diagnosis POS for ≥1 year uncontrolled on one to three antiepileptic drugs were enrolled. Eligible remained stable doses prescribed 8‐week pretreatment baseline phase then randomized (1:1:1) receive (800 or mg/day), placebo, a 14‐week double‐blind phase. Primary efficacy...
Currently, no medications are approved to treat core symptoms of autism spectrum disorder (ASD). One barrier ASD medication development is the lack validated outcome measures able detect symptom change. Current interventions often evaluated using retrospective caregiver reports that describe general clinical presentation but require recall specific behaviors weeks after they occur, potentially reducing accuracy ratings. My JAKE, a mobile and Web-based health (mHealth) app part Janssen Autism...
Objective: The Janssen Autism Knowledge Engine (JAKE®) is a clinical research outcomes assessment system developed to more sensitively measure treatment and identify subpopulations in autism spectrum disorder (ASD). Here we describe JAKE present results from its digital phenotyping (My JAKE) biosensor (JAKE Sense) components. Methods: An observational, non-interventional, prospective study of children adults with ASD was conducted at nine sites the United States. Feedback on usability...